What happened with the FDA and compounded GLP-1s, and who is still operating legally?

The situation with the FDA and compounded GLP-1s (like semaglutide and tirzepatide) has been complex and constantly evolving, primarily driven by drug shortages and safety concerns.

Here's a breakdown of what happened and who is still operating legally:

What Happened with the FDA and Compounded GLP-1s?

1. The Rise of Compounded Versions: When brand-name GLP-1 drugs like Ozempic, Wegovy (semaglutide), Mounjaro, and Zepbound (tirzepatide) started experiencing high demand and shortages, compounding pharmacies began making their own versions. This was appealing due to lower costs and easier access.

2. FDA's Core Concern: Unapproved Active Ingredients (Salt Forms):

   • The FDA-approved drugs (Ozempic, Wegovy, Mounjaro, Zepbound) use specific active pharmaceutical ingredients (APIs): semaglutide base and tirzepatide base.
   • Many compounding pharmacies, however, were using different chemical forms, specifically semaglutide sodium and tirzepatide acetate.
   • The FDA declared that semaglutide sodium and tirzepatide acetate are different active ingredients from the ones approved in the brand-name drugs. Therefore, any compounded product made with these "salt forms" is considered an unapproved new drug and illegal. They haven't been evaluated for safety, efficacy, or quality by the FDA.

3. FDA's Stance on Compounding (General Rules):

   • Compounding is generally allowed when a commercially available drug is not suitable for a patient (e.g., allergies to inactive ingredients, need for a different dosage form) AND the commercially available drug is on the FDA's drug shortage list.
   • Crucially, compounding pharmacies are not allowed to compound a drug that is essentially a copy of a commercially available product when that product is readily available.
   • Even when a drug is on shortage, compounding pharmacies are only supposed to use the exact same API as the brand-name drug (i.e., semaglutide base, not semaglutide sodium).

4. Warnings and Enforcement Actions:

   • The FDA has issued numerous warnings to the public, healthcare providers, and compounding pharmacies about the risks associated with compounded GLP-1s, specifically those made with salt forms.
   • They've highlighted concerns about purity, potency, sterility, potential for harmful impurities, and unknown safety/efficacy.
   • The FDA has sent cease and desist letters to pharmacies and has collaborated with state pharmacy boards to address violations.

5. Current Status: The FDA's stance is firm: most compounded versions of semaglutide and tirzepatide, especially those using salt forms, are illegal and unapproved. The agency continues to monitor and take action against non-compliant pharmacies.

Who is Still Operating Legally (for GLP-1s)?

When it comes to GLP-1 medications, the safest and most legal options are the FDA-approved brand-name drugs, obtained through a licensed healthcare provider and filled at a reputable pharmacy.

1. FDA-Approved Brand-Name Medications:

   • Ozempic (semaglutide, for Type 2 Diabetes)
   • Wegovy (semaglutide, for weight management)
   • Mounjaro (tirzepatide, for Type 2 Diabetes)
   • Zepbound (tirzepatide, for weight management)
   • How to get them legally: You need a prescription from a licensed doctor (MD, DO, NP, PA) after a proper medical evaluation. This prescription is then filled at a licensed retail pharmacy (like CVS, Walgreens, Rite Aid, Kroger Pharmacy, or your local independent pharmacy). These pharmacies dispense the manufacturer's approved product.

2. Compounded GLP-1s (Very Limited & Specific Circumstances):

   • It is extremely rare for a compounding pharmacy to be operating fully legally when producing GLP-1s. For a compounded GLP-1 to be considered legal, all of the following conditions generally must be met:
     • The FDA-approved brand-name drug must be on the FDA's official drug shortage list.
     • The compounding pharmacy must use the exact same active pharmaceutical ingredient (API) as the approved drug (i.e., semaglutide base, not semaglutide sodium; tirzepatide base, not tirzepatide acetate).
     • There must be a specific, documented patient need that cannot be met by the brand-name product (e.g., allergy to an inactive ingredient in the commercial product, need for a different dosage form).
     • The pharmacy must be a properly licensed compounding pharmacy (either 503A or 503B, adhering to strict quality and sterility standards).
   • Given the FDA's strict warnings against "salt forms," finding a compounding pharmacy meeting all these criteria for GLP-1s is challenging, and the FDA still views most such products with high skepticism.

In summary: The FDA has cracked down on compounded GLP-1s primarily because many were using unapproved active ingredients (salt forms) and being sold outside the very narrow legal parameters for compounding. Your safest and most legal path to GLP-1 medication is through a prescription for the FDA-approved brand-name drugs from your doctor, filled at a standard, licensed pharmacy.